Plenty of shares going through on the bell tonight, clearly some individuals or institutions are keen to invest in IMU. That said the company has been somewhat tardy yet again in keeping shareholders abreast of clinical trial updates as and when they occur. I note there have been no updates on the following:
1. The CHECKVACC trial since August 10, 2022
2. The Next Herizon HER VAXX Combination Trial since September 8, 2022
3. The Phase 1a PD1 Vaxx Trial since July 2022 and it’s subsequent combination trial with Roche, and/or
4. Other pre or post clinical trial developments pertaining to all of the above.
Keeping shareholders informed of all material developments in both pre and post clinical trials is all important if you are to continue adding value to shareholders in a biotech stock. I’m confident the team at Imugene are aware of this, but I would ask if possible for them to keep the need for clear and continuous communication in mind when assessing ongoing data. As they are no doubt aware the share price is languishing and all progress reports are of assistance in keeping existing and prospective shareholders engaged. On a positive note information on all of the above must be only weeks if not days away.
Speaking of pre clinical trial results the data presented in the British Medical Journal last month and in Pubmed this month see https://pubmed.ncbi.nlm.nih.gov/37019471/, highlights the fact that hard to reach and treat cancers including liver, lung and pancreatic cancer (just to name a few), have yet again been hunted down and destroyed by Professor Yuman Fong's CF33 virus. 7 out of 8 mice alive after taking CF33 91 days in, 7 out of 8 deceased in the control group. CF33, hunting, finding and eliminating hard to kill cancers from behind the peritoneal (abdominal) cavity. Truly unbelievable in of itself. These results are astonishing to say the least. How they are not worthy of a price sensitive IMU announcement is beyond me, but then again I’m not driving the bus.
Irrespective of a perceived lack of detailed correspondence pertaining to items 1,2,3 and 4 listed above, the documentation and said progression of Imugene’s Vaxinia Trial continues to burn a candle for the majority of IMU shareholders, myself included. Put simply it’s the WOW factor that has most if not all of us on the edge of our seats. Bring on the results of Cohort 3 in the Vaxinia Trial asap, and fast track this breakthrough therapy into patients worldwide, is where the story begins and ends on my watch. If Professor Fong is seeing what he visualised in pre clinical trials with animals, where he eradicated cancer across all NCI 60 cancer lines, bring it on. If he is realising unequivocal evidence of cancer killing within humans, well that’s game set and match, is it not? Dosing solid tumour patients at 10 parts to the 7, closer and closer to the optimal biological dose, without toxicity, within the safety zone, promises to be the game changer for all those sitting on the fence.
Why do people sit on the fence? Do they not believe in the award winning, esteemed, world renowned surgeon and cancer researcher Professor Yuman Fong? Do they reject the claims made by the City of Hope cancer research centre’s leading haematologist Saul Priceman M.D.? Or are they simply waiting to buy when they see everything in black and white, at a time when they shall probably pay up to 200 percent more to own the stock. Perhaps they should talk with shareholders invested in some of the stocks I have written of previously, namely Reata Pharmaceuticals INC. or more recently Neuren Pharmaceuticals Ltd (see herein), for some perspective on waiting for the fish to finally bite.
Seagen recently sold to Pfizer for close to $43 Billion USD, approximately 75 times Imugene’s current value. Yet Seagen in offering a conjugate from which to deliver toxic drugs to cancer cells, is ultimately only as effective as the drugs being delivered. As we now know chemotherapy and monoclonal antibodies such as Keytruda exhibit much higher levels of toxicity and therein side effects, when compared to Imugene’s immune stimulating drugs. Sooner or later, as the FDA considers Imugene’s application for a Phase 1 Oncarlytics trial, as they mull over Professor Fong's biopsies from the current CF33 and Vaxinia trials, those on the fence may be forced to step up and take notice. Though history tells us they often jump to late, for sitting on the fence is far more comfortable than taking the big leap forward. Wikipedia informs us "Sitting on the fence" is a common idiom used in English to describe a person's lack of decisiveness, neutrality or hesitance to choose between two sides in an argument or a competition, or inability to decide due to lack of courage. For many investors it’s much easier to sit on the fence. As an example In 2008, a generational decline in equity markets was accompanied by horrific headlines. Those who were positioned too aggressively suffered about 15 months of severe pain, but those who capitulated with knee-jerk reactions after the collapse did incredibly more damage by selling near the bottom and locking in losses. The Dow thereafter proceeded to explode from 6,500 to 13,000 in three years, at which time investors finally began to ask whether then, three years later, was the time to buy stocks.
Perhaps it's never too late to invest if you have performed the necessary due diligence, research and risk profiling to accomodate your position. Is your investment one in IMU? Imugene can potentially treat a far broader number of individuals than the prospective patient population treated by Reata or Neuren (see above). But when it comes to Imugene the fat lady hasn't sung yet has she. Maybe you should wait another three years until all the perceived risk is off the table. History tells us you may then only be able to buy a third, a fifth or even a tenth of the IMU shares you could buy tomorrow, but they'll be much safer for you won't they.
I for one consider Imugene to be significantly de-risked, given the clinical trial data published thus far. I am firmly in Professor Yuman Fong's corner when it comes to CF33 and Vaxinia. But then again I'm not sitting on the fence am I.
DYOR - Seek investment advice as and when required - Opinions only
) so any success would be life changing but I think we need to be realistic about what to expect.
(20min delay)